Aumake (ASX:AUK) formalised a strategic four-year exclusive global distribution agreement with EZZ Life Sciences (ASX:EZZ).
The partnership establishes an ambitious minimum sales target of $10 million over the duration of the contract, equating to roughly $2.5 million in annual revenue.
The collaboration capitalises on Aumake’s established track record, which has already seen over $2.1 million in sales since 2025 through its robust B2B and B2C channels.
The agreement grants Aumake exclusive rights to a premium suite of EZZ products, including flagship offerings such as EZZ Glutathione Health Support, Vitality Boost, and EZZ Sleep.
Beyond mere distribution, the partnership introduces a cooperative manufacturing model designed to protect and enhance profit margins.
By leveraging Aumake's sophisticated e-commerce platforms and extensive B2B network, the companies aim to penetrate deeper into the global market, with a specific strategic focus on meeting the rising demand in China.
Industry analysts note that this deal targets the highest-margin segment within Aumake’s nutritionals portfolio.
Furthermore, the agreement includes a provision for the co-development of new products, ensuring the partnership remains adaptive to evolving consumer health trends.
At the time of reporting, the share prices of Aumake and EZZ Life Sciences were $0.0030 and $1.70, respectively.